Clarifying the Role of Principal Stratification in the Paired Availability Design

National Institutes of Health, USA.
The International Journal of Biostatistics (Impact Factor: 0.74). 01/2011; 7(1):25. DOI: 10.2202/1557-4679.1338
Source: PubMed


The paired availability design for historical controls postulated four classes corresponding to the treatment (old or new) a participant would receive if arrival occurred during either of two time periods associated with different availabilities of treatment. These classes were later extended to other settings and called principal strata. Judea Pearl asks if principal stratification is a goal or a tool and lists four interpretations of principal stratification. In the case of the paired availability design, principal stratification is a tool that falls squarely into Pearl's interpretation of principal stratification as "an approximation to research questions concerning population averages." We describe the paired availability design and the important role played by principal stratification in estimating the effect of receipt of treatment in a population using data on changes in availability of treatment. We discuss the assumptions and their plausibility. We also introduce the extrapolated estimate to make the generalizability assumption more plausible. By showing why the assumptions are plausible we show why the paired availability design, which includes principal stratification as a key component, is useful for estimating the effect of receipt of treatment in a population. Thus, for our application, we answer Pearl's challenge to clearly demonstrate the value of principal stratification.

10 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pearl (2011) invites researchers to contribute to a discussion on the logic and utility of principal stratification in causal inference, raising some thought-provoking questions. In our commentary, we discuss the role of principal stratification in causal inference, describing why we view the principal stratification framework as useful for addressing causal inference problems where causal estimands are defined in terms of intermediate outcomes. We focus on mediation analysis and principal stratification analysis, showing that they generally involve different causal estimands and answer different questions. We argue that even when principal stratification may not answer the causal questions of primary interest, it can be a preliminary analysis of the data to assess the plausibility of identifying assumptions. We also discuss the use of principal stratification to address issues of surrogate outcomes. Our discussion stresses that a principal stratification analysis should account for all the principal strata and evaluate the distributions of potential outcomes in each of the principal strata. To this end, we view a Bayesian analysis particularly suited for drawing inference on principal strata membership and principal strata effects.
    The International Journal of Biostatistics 01/2012; 8(1). DOI:10.1515/1557-4679.1380 · 0.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The definitive evaluation of treatment to prevent a chronic disease with low incidence in middle age, such as cancer or cardiovascular disease, requires a trial with a large sample size of perhaps 20,000 or more. To help decide whether to implement a large true endpoint trial, investigators first typically estimate the effect of treatment on a surrogate endpoint in a trial with a greatly reduced sample size of perhaps 200 subjects. If investigators reject the null hypothesis of no treatment effect in the surrogate endpoint trial they implicitly assume they would likely correctly reject the null hypothesis of no treatment effect for the true endpoint. Surrogate endpoint trials are generally designed with adequate power to detect an effect of treatment on surrogate endpoint. However, we show that a small surrogate endpoint trial is more likely than a large surrogate endpoint trial to give a misleading conclusion about the beneficial effect of treatment on true endpoint, which can lead to a faulty (and costly) decision about implementing a large true endpoint prevention trial. If a small surrogate endpoint trial rejects the null hypothesis of no treatment effect, an intermediate-sized surrogate endpoint trial could be a useful next step in the decision-making process for launching a large true endpoint prevention trial.
    Journal of the Royal Statistical Society Series A (Statistics in Society) 02/2013; 176(2):603-608. DOI:10.1111/j.1467-985X.2012.01052.x · 1.64 Impact Factor
  • Statistics in Medicine 07/2014; 33(17):3058-9. DOI:10.1002/sim.6168 · 1.83 Impact Factor


10 Reads
Available from